Samenvatting
De ziekte van Gaucher is een zeldzame autosomaal recessief erfelijke lysosomale stapelingsziekte die wordt veroorzaakt door deficiëntie van het lysosomale enzym glucocerebrosidase. Klinische verschijnselen treden op door stapeling van glucosylceramide, het natuurlijk substraat van het deficiënte enzym. De ziekte kent drie varianten: Gaucher type 1 wordt gekenmerkt door anemie, trombocytopenie, hepatosplenomegalie en botafwijkingen; bij de typen 2 en 3 is er tevens sprake van progressieve neurologische verschijnselen. Men spreekt ook wel van de nonneuronopathische vorm versus de neuronopathische vormen van de ziekte. De ziekte van Gaucher type 1 is goed behandelbaar met enzymvervangende therapie en, in sommige omstandigheden, met substraatreductietherapie. Het ziektebeeld wordt geïllustreerd aan de hand van een casus.
Summary
Gaucher disease is a rare autosomal recessive lysosomal storage disorder, due to a deficiency of the lysosomal enzyme glucocerebrosidase. Accumulation of its substrate in macrophages, glucosylceramide, leads to the clinical manifestations of the disorder. Three clinical subtypes are identified. Type-1 Gaucher disease is characterized by the presence of anemia, thrombocytopenia, hepatosplenomegaly and bone abnormalities. Type-2 and type-3 disease are characterized by the presence of primary neurologic disease (non-neuronopathic form versus the neuronopathic forms). Treatment modalities approved for type-1 Gaucher disease are enzyme replacement therapy and substrate reduction therapy. The disease will be illustrated by a case report.
Literatuur
Hollak C, Boot R, Poorthuis B, Aerts J. Van gen naar ziekte; de ziekte van Gaucher. Ned Tijdschr Geneeskd. 2005;149:2163–6.
Grabowski G. Phenotype, diagnosis, and treatment of Gaucher’s disease. Lancet. 2008;372: 1263–71.
Martins A, Valadares E, Porta G, et al. Recommendations on diagnosis, treatment, and monitoring for Gaucher disease. J Pediatr. 2009;155(4 Suppl):S10–8.
Scriver C, Beaudet A, Sly W,Valle D. The metabolic and molecular basis of inherited disease, 8th ed. New York: Mc Graw-Hill, 2001.
Barton N, Brady R, Dambrosia J, et al. Replacement therapy for inherited enzyme deficiency-macrophage-targeted glucocerebrosidase for Gaucher’s disease. N Engl J Med. 1991;324:1464–70.
Hollak C, Aerts J, Oers M van. Treatment of Gaucher’s disease. N Engl J Med. 1993;328:1565–6.
Elstein D, Hollak C, Aerts J, et al. Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease. J Inherit Metab Dis. 2004;27:757–66.
Aerts J, Hollak C, Boot R, et al. Substrate reduction therapy of glycosphingolipid storage disorders. J Inherit Metab Dis. 2006;29:449–56.
Boot R, Verhoek M, Fost M de, et al. Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention. Blood. 2004;103:33–9.
Boot R, Breemen M van,Wegdam W, et al. Gaucher disease: a model disorder for biomarker discovery. Expert Rev Proteomics. 2009;6:411–9.
Hillborg P. Gaucher’s disease in Norrbotten. Nord Med. 1959;61:303–6.
Biegstraaten M, Schaik I van, Aerts J, Hollak C. ‘Non-neuronopathic’ Gaucher disease reconsidered. Prevalence of neurological manifestations in a Dutch cohort of type I Gaucher disease patients and a systematic review of the literature. J Inherit Metab Dis. 2008;31:337–49.
Davies E, Surtees R, DeVille C, et al. A severity scoring tool to assess the neurological features of neuronopathic Gaucher disease. J Inherit Metab Dis. 2007;30:768–82.
Hollak CE, Fost M de, Dussen L van, et al. Enzyme therapy for the treatment of type 1 Gaucher disease: clinical outcomes and dose – response relationships. Expert Opin Pharmacother. 2009;10: 2641–52.
Andersson H, Kaplan P, Kacena K, Yee J. Eightyear clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1. Pediatrics. 2008;122:1182–90.
Cox-Brinkman J, Breemen M van, Maldegem B van, et al. Potential efficacy of enzyme replacement and substrate reduction therapy in three siblings with Gaucher disease type III. J Inherit Metab Dis. 2008;31:745–52.
Author information
Authors and Affiliations
Additional information
fellow metabole ziekten
kinderarts metabole ziekten, Emma Kinderziekenhuis
Aerts, biochemicus
Post, kinderarts
internist metabole ziekten
Rights and permissions
About this article
Cite this article
de Ru, M., Wijburg, F., Aerts, J. et al. Anemie, trombocytopenie en hepatosplenomegalie: de ziekte van Gaucher. TIJDSCHR. KINDERGENEESKUNDE 78, 73–77 (2010). https://doi.org/10.1007/s12456-010-0020-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12456-010-0020-5